A Single Intraarticular Injection of Platelet-Rich Plasma on Pain and Physical Function in Patients With Ankle OA

Sponsor
Kaohsiung Veterans General Hospital. (Other)
Overall Status
Completed
CT.gov ID
NCT04022928
Collaborator
(none)
44
1
1
10.9
4

Study Details

Study Description

Brief Summary

Platelet-rich plasma (PRP) has been reported to be an effective treatment for knee osteoarthritis (OA). The application in ankle OA has rarely been investigated. The aim was to evaluate the efficacy and safety of a single intraarticular injection of PRP for the treatment of patients with ankle OA.

Condition or Disease Intervention/Treatment Phase
  • Other: PRP
N/A

Detailed Description

Methods: In a prospective study, patients with symptomatic ankle OA for at least 6 months were recruited. Patients received a single injection of 3-ml of PRP into symptomatic ankles. The primary outcome was the change from baseline in the visual analog scale (VAS) pain score (0-10cm) at 6 months. Secondary outcomes included the Ankle Osteoarthritis Scale (AOS) score, American Orthopedic Foot and Ankle Society (AOFAS) ankle/hindfoot score, single leg stance test (SLS), use of rescue analgesics and patient satisfaction. Adverse events were recorded during the study.

Patients were followed at 1, 3 and 6 months postinjection .

Study Design

Study Type:
Interventional
Actual Enrollment :
44 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
patients with symptomatic ankle OA for at least 6 months were recruited. Patients received a single injection of 3-ml of PRP into symptomatic ankles.patients with symptomatic ankle OA for at least 6 months were recruited. Patients received a single injection of 3-ml of PRP into symptomatic ankles.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy and Safety of a Single Intraarticular Injection of Platelet-Rich Plasma on Pain and Physical Function in Patients With Ankle Osteoarthritis-a Prospective Study
Actual Study Start Date :
Jul 1, 2018
Actual Primary Completion Date :
Nov 30, 2018
Actual Study Completion Date :
May 30, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: PRP injection

Patients with symptomatic ankle OA for at least 6 months were recruited. Patients received a single injection of 3-ml of PRP into symptomatic ankles.

Other: PRP
, For PRP preparation, specialized platelet concentrate separator containing acid citrate dextrose as anticoagulant and a specific separator gel that harvest PR, preventing contamination of red blood cells and leukocytes were used.

Outcome Measures

Primary Outcome Measures

  1. visual analog scale (VAS) of ankle pain [6 months]

    The patient rated the average severity of ankle pain on ankle movement over the previous week on a 10-cm VAS (0=no pain to 10=worst possible pain)

Secondary Outcome Measures

  1. The Ankle Osteoarthritis Scale (AOS) score [6 months]

    AOS score is a validated patient-rated outcome measure that contains a nine-item pain subscale and a nine-item disability subscale. Using the AOS, a score of 0 represent no pain or disability and 10 represent worst pain or disability imaginable

  2. The American Orthopedic Foot and Ankle Society (AOFAS) ankle/hindfoot score [6 months]

    a 100-point scale that devotes 40 points to pain, 50 points to function and 10 points to alignment. The maximum score of 100 points denotes no pain and normal function and alignment

  3. The single-leg stance (SLS) test [6 months]

    SLS test involved raising the unaffected foot, without touching it to the affected lower extremity, and maintaining balance for as long as possible. Each participant performed three trials, and the best result was recorded

  4. use of analgesic medication [through study completion, an average of 6 months]

    The patient recorded the use of analgesic medication during the study period on a diary card.

  5. global satisfaction [6 months]

    The patients rated his or her level of global satisfaction relative to the state before the treatment, using a 100 mm VAS (0= completely dissatisfied, 100=completely satisfied)

  6. safety of PRP for ankle [through study completion, an average of 6 months]

    The safety of the injection was monitored by recording the occurrence of systemic and local adverse events on a diary card

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age of at least twenty years

  • Ankle pain lasted for at least 6 months, despite conservative treatment or inability to tolerate the side effects of medications

  • Ankle radiographs taken within 6 months (reviewed by the senior author) were equivalent to grade 1-4 osteoarthritis by the Kellgren Lawrence grading system

  • Average ankle pain of > 3cm on a 10-cm visual analog scale (VAS)

  • Radiological evidence of bilateral ankle osteoarthritis was accepted if VAS pain in the contralateral ankle was < 3 cm

  • Normal activity level, not bedridden or confined to a wheelchair, able to walk 30 meters without the aid of a walker, crutches or cane

  • No use of physical therapy or changes in shoes or orthotic devices during the study

Exclusion Criteria:
  • Pregnancy or lactation in women

  • Lower leg trauma in a location other than within the ankle

  • Previous surgery involving the spine, hip or knee

  • The presence of an active infection of the ankle

  • Surgery involving the affected ankle within the previous 12 months

  • Intraarticular steroid or hyaluronate injection in the ankle within the previous 6 months

  • Treatment with anticoagulants or immunosuppressives

  • History of rheumatoid arthritis, gout, or other inflammatory arthropathy

  • The presence of visual or vestibular impairments

  • Poor health status (such as a neoplasm, diabetes mellitus, or paresis) that would interfere with the assessments

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Physical Medicine and Rehabilitation, Veterans General Hospital Kaohsiung Kaohsiung Taiwan 813

Sponsors and Collaborators

  • Kaohsiung Veterans General Hospital.

Investigators

  • Study Director: Shu Fen Sun, MD, Kaohsiung Veterans General Hospital, Taiwan

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Shu-Fen Sun, Director of Neutorehabilitation, MD,Department of Physical Medicine and Rehabilitation, Kaohsiung Veterans General Hospital, Kaohsiung Veterans General Hospital.
ClinicalTrials.gov Identifier:
NCT04022928
Other Study ID Numbers:
  • VGHKS18-CT7-21
First Posted:
Jul 17, 2019
Last Update Posted:
Jul 19, 2019
Last Verified:
Jul 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Shu-Fen Sun, Director of Neutorehabilitation, MD,Department of Physical Medicine and Rehabilitation, Kaohsiung Veterans General Hospital, Kaohsiung Veterans General Hospital.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 19, 2019